

## PHARMACEUTICALS & BIOLOGICS

<b>FANC:</b> Potentiating Melphalan in Multiple Myeloma by Targeting the Fanconi Anemia/BRCA Resistance Pathway	03B097
<b>VEGF/PDGF:</b> Orally Bioavailable Small Molecule that Binds VEGF or PDGF for the Treatment of Cancer or Age-Related Macular Degeneration	03B114
<b>RhoB:</b> Gene Therapy with RhoB Variants to Suppress Cancer Growth	04B102
<b>STAT3:</b> Enhancing Immune Response to Tumor Cells	04B112
<b>MRP1:</b> Compounds for Treating Multidrug Resistance	04MA001
<b>Raf/Mek/P-Erk:</b> Inhibition of the Raf-1/Mek-1/Erk1/2 Pathway by the Beta-2-Adrenergic Receptor Agonist Pirbuterol	05B072
<b>Src, Abl:</b> Dasatinib on Drug-Eluting Stents for the Prevention and Treatment of Restenosis and Stenosis	05B111N
<b>Rb/Raf:</b> Orally active disruptors of the Rb/Raf-1 binding interaction	05B126
<b>Shp2:</b> Indoline Scaffold Protein Tyrosine Phosphatase Inhibitors	06A038
<b>BCR-ABL:</b> Vorinostat co-treatment enhances dasatanib efficacy in CML	06B078N
<b>Rho Kinase:</b> Inhibitors as Novel Anti-Cancer Agents	06B134
<b>Glut-1:</b> Glucose Transporter Inhibitor Antibodies	07B083
<b>SHIP:</b> Inhibitors for Treating Graft vs. Host Disease and Transplant Rejection	08MB010
<b>Topoisomerase II:</b> Inhibitors of Nuclear Export of Topoisomerase II Alpha	08MB014
<b>Aurora:</b> Aurora A Kinase Inhibitors	09MA037
<b>pH:</b> Inhibition of Metastasis with Systemic Non-volatile Buffers	09MB048
<b>Mcl-1:</b> Asymmetrical Marinopyrroles as Anti-Cancer Agents	10MA018N
<b>LPAAT:</b> Lysophosphatidic Acid Acyltransferase-Beta Inhibitors to Treat Pancreatic Cancer	10MA019N
<b>FT/GGT:</b> Farnesyltransferase/ Geranylgeranyltransferase Dual Inhibitor	10MB048
<b>Topoisomerase II:</b> Inhibitor Enhancer in Multiple Myeloma	10MB078
<b>Proteasome:</b> Non-covalent and Reversible Proteasome Inhibitors with an Oxadiazole-isopropylamide Core	10MB083
<b>SHP2:</b> Novel Small Molecule Oxindole Tyrosine Phosphatase Inhibitor	12MA024N
<b>HDAC6:</b> Novel Small Molecule Histone Deacetylase 6 Inhibitor with a Substituted Aryl Urea Cap Group	12MA030
<b>Mcl-1/Bcl-xL:</b> Cyclic, Symmetrical and Asymmetrical Marinopyrroles as Anti-Cancer Agents	12MA035N
<b>IRE-1:</b> Novel Small Molecule Inhibitors of IRE-1 for Treatment of B-cell Cancer	12MB089
<b>STAT3:</b> STAT3 Dimerization Inhibitors	12MB098
<b>Anti-infectives:</b> Symmetrical Synthetic Marinopyrroles as anti-MRSA Therapeutics	12MB110
<b>BRD4 JAK2:</b> Novel BRD4/JAK2 Dual Inhibitors as Cancer Therapeutics	14MB069
<b>WEE1:</b> Small molecule WEE1 inhibitor to treat cancer that inhibits WEE1 phosphorylation of H2B but not Cdc2	14MB092N
<b>Ras:</b> Inhibitors of the Binding of GTP to Oncogenic Mutant K-Ras	15MA011
<b>Ras/Raf:</b> Stapled Peptides Designed to Inhibit the K-Ras/Raf Interaction	15MA012
<b>Aurora/JAK2:</b> Dual Kinase Inhibitor targeting JAK2 and Aurora Kinase A for GVHD Prophylaxis	16MA005N
<b><math>\beta</math>-catenin/BCL-9:</b> Small molecule inhibitors of the interaction of $\beta$ -catenin and BCL-9	17MA014
<b><math>\beta</math>-catenin/TCF:</b> Small molecule inhibitors of the interaction of $\beta$ -catenin and T-cell Factor	17MB040N

### FOR ADDITIONAL INFORMATION CONTACT

Haskell Adler PhD MBA CLP  
 Sr. Licensing Manager, Registered Patent Agent  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
 (813) 745-6596

Jarett Rieger Esq. MBA  
 Sr. Director, Innovation Office  
[jarett.rieger@moffitt.org](mailto:jarett.rieger@moffitt.org)  
 (813) 745-6828

DIAGNOSTICS, IMMUNOTHERAPIES,  
 DEVICES, TOOLS, SOFTWARE

5.10.2018



## IMMUNOTHERAPIES

<b>Vaccine Adjuvant:</b> Flagellin-Based Adjuvant for Tumor Cell Vaccines that binds TLR5	04A028
<b>Antibodies:</b> MARCO for Enhanced Dendritic Cell Vaccine Efficacy	07MB004
<b>Vaccine:</b> Vaccines Using Synthetic Peptide-Poly IC Complexes that Elicit T-cell Responses Comparable to Live Vaccination	11MA013
<b>TAG72-CD3:</b> Bispecific Antibody for Targeted Cancer Immunotherapy	14MB072
<b>Cancer Vaccine:</b> Full-Length Variant Survivin Vaccine Potentiates Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma	14MB098
<b>TLR9:</b> CAR-T cell constructs (chimeric antigen receptors) that Recognize TLR9	16MA025
<b>DOR:</b> Delta opioid receptor ligand and anti-PD1 checkpoint inhibitor conjugates for immunotherapy of lung cancer	16MA029N
<b>AaPC:</b> Artificial Antigen-Presenting Cells with Heparin-Binding Domain for Producing CAR-Ts	16MB049
<b>AaPC:</b> Artificial Antigen-Presenting Cells for Expanding TILs/MILs in Cancer Immunotherapy	16MB050
<b>TAG72:</b> CAR-T cell constructs (chimeric antigen receptors) that Recognize TAG72	16MB057
<b>IL-13R<math>\alpha</math>2:</b> CAR-T cell constructs (chimeric antigen receptors) that Recognize IL-13R $\alpha$ 2	16MB069
<b>CD3-CD28:</b> Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy	17MA007
<b>TILs:</b> Simple and Rapid Method for Culture of TILs from Melanoma Tumor Fragments or Core Needle Biopsies of Solid Tumors	17MA012
<b>CLEC12A:</b> CAR-T cell constructs (chimeric antigen receptors) that Recognize CLEC12A to Treat AML	17MA041
<b>CD99:</b> CAR-T cell constructs (chimeric antigen receptors) that Recognize CD99 to Treat AML	17MA042
<b>MIC &amp; RAET1/ULBP:</b> CAR-T CELL constructs that use the NKG2D protein to bind MIC and RAET1/ULBP proteins to treat AML	18MA023N

## DIAGNOSTICS

<b>Protein Diagnostic:</b> Characterization of Quantum Dots for Ovarian Cancer Detection	04A064
<b>Protein Signature:</b> Discriminating Common Adenocarcinomas	05A014
<b>Genetic Signature:</b> Metastatic Melanoma Stage Identification	06B073
<b>Plasma Protein Biomarker:</b> Diagnosis of Ovarian Cancer	06B098
<b>Protein Biomarker:</b> Predicting Response to Immunosuppression in MDS	07A056
<b>Genetic Signature:</b> Predicting Tumor Aggressiveness	07B108
<b>Protein Biomarker:</b> Diagnostic Marker for AML and MPD	07B113
<b>Genetic Signature:</b> Malignancy Risk Signature to Predict High-Risk Normal Breast Tissues	08A016
<b>Antibody Diagnostic:</b> Monitoring Multiple Myeloma Progression and Recurrence	08MA005
<b>Genetic Signature:</b> Lymph Node Formation for Prognosis of Colorectal Cancer	09MA014
<b>Protein Biomarker/Genetic Signature:</b> Diagnostic for the Classification of Carcinomas of Unknown Primary Site (CUP)	10MA009
<b>Genetic Signature:</b> Predicting High Grade Glioma Outcomes Using Senescence Associated Genes	10MA013
<b>Molecular Imaging Probe:</b> Non-invasive Detection of Breast Cancer in Lymph Nodes	10MA024
<b>Molecular Imaging Probe:</b> Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery	10MB069N
<b>Genetic Signature:</b> CREB Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking	11MA006
<b>Protein Diagnostic:</b> Protein-Protein Interaction (PPI) Biomarkers	11MA014
<b>Imaging:</b> Digital Pathology Tool to Grade Breast Cancer Histological Images	11MA022

### FOR ADDITIONAL INFORMATION CONTACT

#### PHARMACEUTICALS & BIOLOGICS

Haskell Adler PhD MBA CLP  
 Sr. Licensing Manager, Registered Patent Agent  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
 (813) 745-6596

Jarett Rieger Esq. MBA  
 Sr. Director, Innovation Office  
[jarett.rieger@moffitt.org](mailto:jarett.rieger@moffitt.org)  
 (813) 745-6828

#### DIAGNOSTICS, DEVICES TOOLS, SOFTWARE



## DIAGNOSTICS (cont.)

<b>Molecular Imaging Probe:</b> Surrogate Markers for Colon Adenoma and Adenocarcinoma	11MA026N
<b>Genetic Signature:</b> Method of Detecting MDS Using hTERT Activity	11MB061N
<b>Molecular Imaging Probe:</b> Intraoperative Detection of Pancreatic Cancer Using Targeted Fluorescent Probes	11MB064
<b>Genetic Signature:</b> Predicting Response to Cancer Immunotherapy	11MB069
<b>Protein Signature:</b> Method of Diagnosing Chronic Lymphocytic Leukemia	11MB072N
<b>Protein Diagnostic:</b> Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins	11MB087N
<b>Genetic Signature:</b> Five Gene Signature Predicts Overall and Recurrence-Free Survival in NSCLC	12MA023N
<b>Genetic Signature:</b> O-glycan Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking	12MA034
<b>Genetic Signature:</b> Determining Prostate Cancer Recurrence Using Polymorphisms In Angiogenesis Genes	12MA045
<b>Molecular Imaging Probe:</b> Probes for Lung Cancer Intraoperative Guidance	12MA050N
<b>Genetic Signature:</b> E2F/Rb pathway signature to predict patient benefit from adjuvant chemo in NSCLC	12MA069
<b>Molecular Imaging Probe:</b> A Novel <sup>18</sup> F Scaffold for Preparing Targeted PET Imaging Probes	12MB104
<b>Protein Diagnostic:</b> Phosphorylated STAT3 Protein as a Biomarker of Graft Versus Host Disease	13MA002
<b>Multiplex Diagnostic:</b> RNA Sequencing and Mass Spectrometric Method for Detecting Minimal Residual Disease in Multiple Myeloma	13MA009
<b>Genetic Signature:</b> Predicting Recurrence and Benefit From Adjuvant Chemotherapy in Colorectal Cancer	13MA036
<b>Imaging:</b> Decision Support Tool for Oncology Treatment that Analyzes Radiological Images	13MB047
<b>Cell Imaging:</b> Apparatus and Method for Selecting Cancer Treatment Regimens for Multiple Myeloma	13MB048N
<b>Molecular Imaging:</b> Texture Feature Analysis of Low-Dose CT Images for Pulmonary Nodule Diagnosis	13MB054
<b>Molecular Imaging:</b> Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma	13MB055
<b>Molecular Imaging:</b> Novel PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging	13MB056N
<b>miRNA Diagnostic:</b> Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs)	13MB078
<b>miRNA Diagnostic:</b> Signature to Predict Progression of Barrett's Esophagus to Esophageal Dysplasia or Adenocarcinoma	13MB080
<b>Protein Biomarker:</b> Expression of WEE1 and PAXIP1 Can Select Patients who Respond to WEE1 Inhibitor Therapy	14MA001
<b>Genetic Signature:</b> Predicting Distant Metastasis in Stage I Lung Cancer Patients Treated with Surgery	14MA008
<b>Genetic Signature:</b> Microarray-based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy	14MA052N
<b>Molecular Imaging:</b> Monoacylated TLR2 Ligand Fluorescent Probe for Detection and Tumor Removal in Pancreatic Cancer Patients	15MA015
<b>Diagnostic:</b> Intracellular S100A9 Alone or NLRP3 Inflammasome Activation May Be Specific Biomarkers for MDS	15MA021N
<b>Diagnostic:</b> S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration	15MA031N
<b>Molecular Imaging Probe:</b> In vivo Positron Emission Tomography-Based Perfusion/Blood Pool Imaging Using Labeled Erythrocytes	15MB042N

### FOR ADDITIONAL INFORMATION CONTACT

#### DIAGNOSTICS, IMMUNOTHERAPIES PHARMACEUTICALS & BIOLOGICS

Haskell Adler PhD MBA CLP  
 Sr. Licensing Manager, Registered Patent Agent  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
 (813) 745-6596

Jarett Rieger Esq. MBA  
 Sr. Director, Innovation Office  
[jarett.rieger@moffitt.org](mailto:jarett.rieger@moffitt.org)  
 (813) 745-6828

#### DIAGNOSTICS DEVICES, TOOLS SOFTWARE



## DIAGNOSTICS (cont.)

<b>Protein Biomarker:</b> Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression	15MB065
<b>Genetic Signature:</b> Diagnostic to Distinguish Lung Carcinoma from Metastatic Head & Neck Carcinoma	16MB040
<b>Protein Biomarker:</b> Measuring MRE11 in Muscle-Invasive Bladder Cancer to Predict whether Cystectomy (bladder removal) would have a Better Outcome than Bladder-sparing Therapy with Chemoradiation	16MB041
<b>Protein Biomarker:</b> Predicting Restoration of Sensitivity to Erythropoietin in MDS Patients treated with Lenalidomide	16MB042
<b>Molecular Imaging Probe:</b> Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent	16MB044
<b>miRNA Diagnostic:</b> Signature to Predict Progression of Barrett's Esophagus to Esophageal Dysplasia or Adenocarcinoma	16MB066
<b>miRNA Diagnostic:</b> miRNA Signature combined with Radiological Features for Non-invasive Early Detection of Malignancy in IPMN	17MA001
<b>Genetic Biomarker:</b> PTEN Mutation as a Biomarker of Response to GGTI-2418 Treatment in Cancer	17MA025

## DEVICES, TOOLS & SOFTWARE

<b>Med Device:</b> Objective Imaging Reference Standards	07A049
<b>Med Device:</b> Ventana Inline Dispenser Float Mechanism	09MB053
<b>Med Device:</b> Handheld Radioisotope Identification Device (RIID)	10MB054
<b>Med Device:</b> Muscle Stapler	10MB065N
<b>Med Device:</b> Pump-assisted High Flow Rate Isolated Limb Infusion for Regional Cancer Treatment	11MB017N
<b>Med Device:</b> Minimally Invasive Spinal Fusion Using a Transdiscal Screw System	11MA021
<b>Med Device:</b> Vascular Stent for Anastomosis	12MA054N
<b>Med Device:</b> Arterial Line Catheter Modification	12MA067
<b>Med Device:</b> Improved Enteral Feeding Tube and Retention Disc to Reduce Dislodgement, Infection and Complications	13MA001
<b>Med Device:</b> Improved Orogastric Tube Guide	13MA030
<b>Med Device:</b> Expandable Intervertebral Cage for Spinal Fusion	14MB067N
<b>Med Device:</b> Improved Pigtail Drainage Catheter for Percutaneous Fluid Aspiration	15MA034
<b>Med Device:</b> Safety Catheter with Needle and Blood Exposure Prevention Systems	15MB064
<b>Med Device:</b> Novel Endotracheal Tube Intubating Stylet	16MA021
<b>Med Device:</b> Anesthesia Intra-oral Monitoring System (AIMS) (Replacement for the Nasal Cannula)	16MB046
<b>Research Tool:</b> Novel Electroporation Buffer Formulation for Enhanced Efficiency and Viability	05B141
<b>Software:</b> Method for Improved Detection of Lung Function and Management of Lung Cancer Radio Therapy	10MA037N
<b>Software:</b> Method for Improving the Accuracy of Charged Particle Beam Radiotherapy	12MB072
<b>Software:</b> Automated Technique for Generating BIRADS Scores from Mammograms	13MA025
<b>Software:</b> BMT Research Analysis Information Network (BRAIN)	13MA053
<b>Software:</b> Decision Support Tool for Oncology Treatment using Mathematical Simulations	13MB073
<b>Software:</b> A Quantitative Framework to Identify Radiation Targets for Cancer Treatment that Synergize with Immunotherapy (Abscopal Effect)	14MA022
<b>Software:</b> Negative Information Storage Model for Genomic Data	15MA033
<b>Copyright:</b> Energize mBC: Web-based Program to Treat Fatigue in Metastatic Breast Cancer Patients	17MC003

### PHARMACEUTICALS & BIOLOGICS, DIANOSTICS IMMUNOTHERAPIES

Haskell Adler PhD MBA CLP  
 Sr. Licensing Manager, Registered Patent Agent  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
 (813) 745-6596

Jarett Rieger Esq. MBA  
 Sr. Director, Innovation Office  
[jarett.rieger@moffitt.org](mailto:jarett.rieger@moffitt.org)  
 (813) 745-6828

